2016 All Hands Meeting
November 16 Session
Life Sciences Track Agenda

Product Liability Update for Life Science Companies

Sandra Edwards & Karen Kimmey
Farella Braun + Martel LLP

Hope for the best, plan for the worst. Adverse incidents, during and after development of life science products, can lead to individual and class action claims stemming from research, design, manufacture, distribution or marketing. Product liability litigation is constantly evolving, and this presentation will update in-house counsel at life science companies about recent developments and trends for avoiding future claims and defending current ones.

Un-“Predictable Arts” – What Life Sciences Can Learn From Tech About Licensing, Trolls, and Patentable Subject Matter

Teresa Lavoie & Eric Schulman
Fish & Richardson P.C.

The first half of the double-length session will update in-house counsel at life sciences and healthtech companies on current IP portfolio management strategies and their implications for due diligence, patent prosecution and licensing. Speakers will also provide lessons from the world of high tech that are applicable to healthtech, as more companies enter this emerging area.

FDA Update

Scott Lassman

The second half of the double-length session will update in-house counsel at life science companies on current developments at the Food and Drug Administration, including Hatch-Waxman and clinical trial disclosure rules.

HIPAA Update

Jodi Daniel & Kristin Madigan
Crowell & Moring LLP

Healthcare IT continues to grow explosively, and with it the need to stay current on evolving HIPAA issues, including audits, privacy notices, cybersecurity, breach notification, OCR investigations, documentation and corrective action. This presentation will review recent developments and responsive strategies for life science companies.

Life Science Sector Collaborations

Lila Hope/Usha Arunachalam
Cooley LLP/The Leukemia & Lymphoma Society

When would it be beneficial to expand a clinical trial beyond the traditional model of characterizing the safety and efficacy of a particular study drug? How can we best arrange such a clinical study using drugs from multiple pharmaceutical companies, in order to maximize our understanding of the uses of various drugs for a particular disease, protection the intellectual property for each pharma participant, but also to minimize the likelihood of intellectual property ownership overlap? We will explore these questions through a recent case study.

International Corruption Enforcement: Recent Development, Trends and Strategies

Brendan Cullen & Laura Oswell
Sullivan & Cromwell LLP

The stakes have never been higher for global companies active in emerging markets. The U.S. Foreign Corrupt Practices Act (FCPA) has led to more than 400 SEC and DOJ enforcement actions involving more than 100 countries but with particular focus on critical markets like China. To address evolving demands of the FCPA and similar laws, in-house counsel must be prepared to develop strategies and respond to these complex issues. This session will discuss worldwide anti-corruption enforcement, recent policy developments and trends and strategies for implementing robust compliance programs and responding to alleged compliance breaches.

Please Note: Program details are subject to change without notice

2016 Participating Law Firms & Companies